Can an immune-regulatory vaccine prevent HIV infection?

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 3, 2012, Pages 299-305

  Boettler, Tobias ^a   Cunha Neto, Edecio ^b   Kalil, Jorge ^b   Von Herrath, Matthias ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

HIV; immune regulation; T cells; vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT INTERLEUKIN 10;

ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG RESEARCH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; IMMUNOREGULATION; INFECTION PREVENTION; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TREATMENT FAILURE; VACCINATION; VACCINE PRODUCTION; VIRUS CELL TRANSFORMATION; VIRUS REPLICATION;

AIDS VACCINES; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HUMANS; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; MICE; T-LYMPHOCYTES, REGULATORY; VIRUS REPLICATION;

EID: 84858215945     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.178     Document Type: Review

References (62)

1. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8(4), 247-258 (2008). (Pubitemid 351432801)
2. Johnston MI, Fauci AS. An HIV vaccine -challenges and prospects. N. Engl. J. Med. 359(9), 888-890 (2008).
3. Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat. Med. 15(8), 866-870 (2009).
4. Walker LM, Burton DR. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr. Opin. Immunol. 22(3), 358-366 (2010).
5. Buchbinder SP, Mehrotra DV, Duerr A et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372(9653), 1881-1893 (2008).
6. HIV vaccine failure prompts Merck to halt trial. Nature 449 (2007).
7. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361(23), 2209-2220 (2009).
8. Douek DC, Brenchley JM, Betts MR et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417(6884), 95-98 (2002). (Pubitemid 34498823)
9. Rosa DS, Ribeiro SP, Almeida RR et al. A DNA vaccine encoding multiple HIV CD4 epitopes elicits vigorous polyfunctional, long-lived CD4+ and CD8+ T cell responses. PLoS One 6(2), e16921 (2011).
10. van Asten L, Danisman F, Otto SA et al. Pre-seroconversion immune status predicts the rate of CD4 T cell decline following HIV infection. AIDS 18(14), 1885-1893 (2004). (Pubitemid 39313204)
11. Deeks SG, Kitchen CM, Liu L et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 104(4), 942-947 (2004). (Pubitemid 39038012)
12. Hazenberg MD, Otto SA, van Benthem BH et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 17(13), 1881-1888 (2003). (Pubitemid 37070273)
13. Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RM. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J. Immunol. 169(6), 3400-3406 (2002). (Pubitemid 35013190)
14. Naicker DD, Werner L, Kormuth E et al. Interleukin-10 promoter polymorphisms influence HIV-1 susceptibility and primary HIV-1 pathogenesis. J. Infect. Dis. 200(3), 448-452 (2009).
15. Shin HD, Winkler C, Stephens JC et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc. Natl Acad. Sci. USA 97(26), 14467-14472 (2000). (Pubitemid 32016599)
16. Hansen SG, Ford JC, Lewis MS et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473(7348), 523-527 (2011).
17. Wilson NA, Keele BF, Reed JS et al. Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J. Virol. 83(13), 6508-6521 (2009).
18. Ruprecht RM. Passive immunization with human neutralizing monoclonal antibodies against HIV-1 in macaque models: experimental approaches. Methods Mol. Biol. 525, 559-566, xiv (2009).
19. McElrath MJ, De Rosa SC, Moodie Z et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372(9653), 1894-1905 (2008).
20. Sandler NG, Wand H, Roque A et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J. Infect. Dis. 203(6), 780-790 (2011).
21. Douek D. HIV disease progression: immune activation, microbes, and a leaky gut. Top HIV Med. 15(4), 114-117 (2007).
22. Kosmrlj A, Read EL, Qi Y et al. Effects of thymic selection of the T-cell repertoire on HLA Class 1-associated control of HIV infection. Nature 465(7296), 350-354 (2010).
23. Jennes W, Evertse D, Borget MY et al. Suppressed cellular alloimmune responses in HIV-exposed seronegative female sex workers. Clin. Exp. Immunol. 143(3), 435-444 (2006).
24. Koning FA, Otto SA, Hazenberg MD et al. Low-level CD4+ T cell activation is associated with low susceptibility to HIV-1 infection. J. Immunol. 175(9), 6117-6122 (2005). (Pubitemid 41508099)
25. Card CM, McLaren PJ, Wachihi C, Kimani J, Plummer FA, Fowke KR. Decreased immune activation in resistance to HIV-1 infection is associated with an elevated frequency of CD4(+)CD25(+)FOXP3(+) regulatory T cells. J. Infect. Dis. 199(9), 1318-1322 (2009).
26. McLaren PJ, Ball TB, Wachihi C et al. HIV-exposed seronegative commercial sex workers show a quiescent phenotype in the CD4+ T cell compartment and reduced expression of HIV-dependent host factors. J. Infect. Dis. 202(Suppl. 3), S339-S344 (2010).
27. Begaud E, Chartier L, Marechal V et al. Reduced CD4 T cell activation and in vitro susceptibility to HIV-1 infection in exposed uninfected Central Africans. Retrovirology 3, 35 (2006).
28. Kollmann TR, Pettoello-Mantovani M, Katopodis NF et al. Inhibition of acute in vivo human immunodeficiency virus infection by human interleukin 10 treatment of SCID mice implanted with human fetal thymus and liver. Proc. Natl Acad. Sci. USA 93(7), 3126-3131 (1996). (Pubitemid 26114375)
29. Naicker DD, Wang B, Losina E et al. Association of IL-10-promoter genetic variants with the rate of CD4 T-cell loss, IL-10 plasma levels, and breadth of cytotoxic T-cell lymphocyte response during chronic HIV-1 infection. Clin. Infect. Dis. 54(2), 294-302 (2011).
30. Erikstrup C, Kallestrup P, Zinyama-Gutsire RB et al. Reduced mortality and CD4 cell loss among carriers of the interleukin-10-1082G allele in a Zimbabwean cohort of HIV-1-infected adults. AIDS 21(17), 2283-2291 (2007). (Pubitemid 350287454)
31. Than S, Hu R, Oyaizu N et al. Cytokine pattern in relation to disease progression in human immunodeficiency virus-infected children. J. Infect. Dis. 175(1), 47-56 (1997). (Pubitemid 27020823)
32. Li Q, Estes JD, Schlievert PM et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 458(7241), 1034-1038 (2009).
33. Onanga R, Kornfeld C, Pandrea I et al. High levels of viral replication contrast with only transient changes in CD4(+) and CD8(+) cell numbers during the early phase of experimental infection with simian immunodeficiency virus SIVmnd-1 in Mandrillus sphinx. J. Virol. 76(20), 10256-10263 (2002).
34. Silvestri G, Sodora DL, Koup RA et al. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 18(3), 441-452 (2003). (Pubitemid 36351522)
35. Chakrabarti LA. The paradox of simian immunodeficiency virus infection in sooty mangabeys: active viral replication without disease progression. Front. Biosci. 9, 521-539 (2004). (Pubitemid 39043732)
36. Kornfeld C, Ploquin MJ, Pandrea I et al. Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. J. Clin. Invest. 115(4), 1082-1091 (2005). (Pubitemid 40489413)
37. Jacquelin B, Mayau V, Targat B et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled Type 1 IFN response. J. Clin. Invest. 119(12), 3544-3555 (2009).
38. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3(3), 253-257 (2003). (Pubitemid 37323210)
39. Legrand FA, Nixon DF, Loo CP et al. Strong HIV-1-specific T cell responses in HIV-1-exposed uninfected infants and neonates revealed after regulatory T cell removal. PLoS One 1, e102 (2006).
40. Chase AJ, Yang HC, Zhang H, Blankson JN, Siliciano RF. Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus Type 1-infected elite suppressors correlates with low CD4+ T-cell activation. J. Virol. 82(17), 8307-8315 (2008).
41. Jiang Q, Zhang L, Wang R et al. FoxP3+CD4+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2-/-gC-/-mice in vivo. Blood 112(7), 2858-2868 (2008).
42. Nilsson J, Boasso A, Velilla PA et al. HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/ AIDS. Blood 108(12), 3808-3817 (2006). (Pubitemid 44864563)
43. Eggena MP, Barugahare B, Jones N et al. Depletion of regulatory T cells in HIV infection is associated with immune activation. J. Immunol. 174(7), 4407-4414 (2005). (Pubitemid 40396024)
44. Battaglia M, Roncarolo MG. The fate of human Treg cells. Immunity 30(6), 763-765 (2009).
45. Monteiro P, Gosselin A, Wacleche VS et al. Memory CCR6+CD4+ T cells are preferential targets for productive HIV Type 1 infection regardless of their expression of integrin b7. J. Immunol. 186(8), 4618-4630 (2011).
46. Dunham RM, Cervasi B, Brenchley JM et al. CD127 and CD25 expression defines CD4+ T cell subsets that are differentially depleted during HIV infection. J. Immunol. 180(8), 5582-5592 (2008).
47. Huber S, Gagliani N, Esplugues E et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3(-) and Foxp3(+) regulatory CD4(+) T cells in an interleukin-10-dependent manner. Immunity 34(4), 554-565 (2011).
48. Angel JB, Jacobson MA, Skolnik PR et al. A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects. AIDS 14(16), 2503-2508 (2000).
49. Weissman D, Ostrowski M, Daucher JA et al. Interleukin-10 decreases HIV plasma viral load: results of a Phase 1 clinical trial. Presented at: 4th Conference Retroviruses Opportunistic Infections January 1997. Washington DC, USA (1997) (Abstract no. 37).
50. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J. Exp. Med. 205(1), 7-12 (2008).
51. Sato K, Yamashita N, Baba M, Matsuyama T. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 18(3), 367-379 (2003). (Pubitemid 36351516)
52. Sato K, Yamashita N, Baba M, Matsuyama T. Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood 101(9), 3581-3589 (2003). (Pubitemid 36857945)
53. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting Type 1 regulatory T cells in rodents and humans. Immunol. Rev. 212, 28-50 (2006). (Pubitemid 44116698)
54. Coon B, An LL, Whitton JL, von Herrath MG. DNA immunization to prevent autoimmune diabetes. J. Clin. Invest. 104(2), 189-194 (1999).
55. Bento CA, Hygino J, Andrade RM et al. IL-10-secreting T cells from HIV-infected pregnant women downregulate HIV-1 replication: effect enhanced by antiretroviral treatment. AIDS 23(1), 9-18 (2009).
56. Moreno-Fernandez ME, Rueda CM, Rusie LK, Chougnet CA. Regulatory T cells control HIV replication in activated T cells through a cAMP-dependent mechanism. Blood 117(20), 5372-5380 (2011).
57. Favre D, Lederer S, Kanwar B et al. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog. 5(2), e1000295 (2009).
58. Kanwar B, Favre D, McCune JM. Th17 and regulatory T cells: implications for AIDS pathogenesis. Curr. Opin. HIV AIDS 5(2), 151-157 (2010).
59. Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J. Virol. 78(5), 2454-2459 (2004). (Pubitemid 38228938)
60. Weiss L, Donkova-Petrini V, Caccavelli L, Balbo M, Carbonneil C, Levy Y. Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood 104(10), 3249-3256 (2004). (Pubitemid 39507143)
61. Roncarolo MG, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat. Rev. Immunol. 7(8), 585-598 (2007). (Pubitemid 47123554)
62. Fauci AS. Fauci: why there is no AIDS vaccine. www.msnbc.msn.com/id/ 29898087/ns/ health-aids/t/fauci-why-there-no-aids-vaccine/#.TymdgflEFD8